Y-mAbs Therapeutics (YMAB) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

YMAB Stock Forecast


Y-mAbs Therapeutics stock forecast is as follows: an average price target of $20.00 (represents a 98.02% upside from YMAB’s last price of $10.10) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

YMAB Price Target


The average price target for Y-mAbs Therapeutics (YMAB) is $20.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $13.00. This represents a potential 98.02% upside from YMAB's last price of $10.10.

YMAB Analyst Ratings


Buy

According to 6 Wall Street analysts, Y-mAbs Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for YMAB stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Y-mAbs Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 11, 2024Etzer DaroutBMO Capital$24.00$15.0659.36%137.62%
Jun 28, 2024Nicole GerminoTruist Financial$21.00$12.3370.32%107.92%
May 10, 2024Robert BurnsH.C. Wainwright$22.00$12.8770.94%117.82%
Apr 05, 2024Etzer DaroutBMO Capital$26.00$14.5678.57%157.43%
May 10, 2023YMAB)to OutperformWedbush$13.00$9.8931.38%28.71%
Row per page
Go to

The latest Y-mAbs Therapeutics stock forecast, released on Nov 11, 2024 by Etzer Darout from BMO Capital, set a price target of $24.00, which represents a 59.36% increase from the stock price at the time of the forecast ($15.06), and a 137.62% increase from YMAB last price ($10.10).

Y-mAbs Therapeutics Price Target by Period


1M3M12M
# Anlaysts114
Avg Price Target$24.00$24.00$23.25
Last Closing Price$10.10$10.10$10.10
Upside/Downside137.62%137.62%130.20%

In the current month, the average price target of Y-mAbs Therapeutics stock is $24.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 137.62% increase as opposed to Y-mAbs Therapeutics's last price of $10.10. This month's average price target is down 0.00% compared to last quarter, and up 3.23% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 09, 2024Cantor FitzgeraldUnderperformUnderperformHold
Sep 09, 2024Morgan StanleyBuyBuyHold
Aug 16, 2024Cantor Fitzgerald-OverweightInitialise
Aug 13, 2024Morgan StanleyBuyBuyHold
Aug 13, 2024BMO CapitalUnderperformUnderperformHold
May 10, 2024H.C. WainwrightBuyBuyHold
Apr 05, 2024BMO CapitalOutperformOutperformHold
May 10, 2023Wedbush-OutperformUpgrade
Jan 05, 2023Cowen & Co.-Market PerformDowngrade
Oct 31, 2022GuggenheimBuyBuyHold
Row per page
Go to

Y-mAbs Therapeutics's last stock rating was published by Cantor Fitzgerald on Sep 09, 2024. The company gave YMAB a "Underperform" rating, the same as its previous rate.

Y-mAbs Therapeutics Financial Forecast


Y-mAbs Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
Revenue--------$23.36M$20.45M$20.75M$20.25M$31.45M$12.54M$10.80M$10.49M$9.60M$8.96M$10.95M$5.38M$20.75M
Avg Forecast$28.54M$25.96M$26.28M$24.82M$26.85M$23.28M$23.02M$22.21M$20.95M$20.97M$20.33M$15.58M$20.35M$12.01M$11.23M$10.90M$10.77M$10.87M$7.33M$41.84M$11.59M
High Forecast$31.64M$28.78M$29.13M$27.54M$28.19M$23.58M$25.52M$22.21M$22.15M$20.97M$22.53M$17.27M$22.56M$12.01M$11.23M$10.90M$10.77M$10.87M$7.33M$41.84M$11.59M
Low Forecast$25.96M$23.62M$23.91M$22.09M$25.11M$22.97M$20.94M$22.21M$19.60M$20.97M$18.49M$14.17M$18.51M$12.01M$11.23M$10.90M$10.77M$10.87M$7.33M$41.84M$11.59M
# Analysts111354224222111122222
Surprise %--------1.12%0.98%1.02%1.30%1.55%1.04%0.96%0.96%0.89%0.82%1.49%0.13%1.79%

Y-mAbs Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $22.21M, with a low forecast of $22.21M, and a high forecast of $22.21M. YMAB's average Quarter revenue forecast represents a -4.95% decrease compared to the company's last Quarter revenue of $23.36M (Dec 23).

Y-mAbs Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111354224222111122222
EBITDA--------$-74.00K$-7.75M$-7.22M$-7.50M$-1.15M$-25.79M$-39.76M$-27.50M$-35.47M$-28.56M$-22.50M$33.88M$-19.82M
Avg Forecast$-13.14M$-11.96M$-12.10M$-11.43M$-12.37M$-10.72M$-10.60M$-37.05M$-9.65M$-9.66M$-9.36M$-33.68M$-30.65M$-5.39M$-5.03M$-30.62M$-4.83M$-4.87M$-3.28M$-18.76M$-5.20M
High Forecast$-11.96M$-10.88M$-11.01M$-10.17M$-11.57M$-10.58M$-9.64M$-29.64M$-9.03M$-9.66M$-8.52M$-26.95M$-24.52M$-5.39M$-5.03M$-24.50M$-4.83M$-4.87M$-3.28M$-18.76M$-5.20M
Low Forecast$-14.57M$-13.25M$-13.42M$-12.69M$-12.98M$-10.86M$-11.75M$-44.46M$-10.20M$-9.66M$-10.38M$-40.42M$-36.78M$-5.39M$-5.03M$-36.75M$-4.83M$-4.87M$-3.28M$-18.76M$-5.20M
Surprise %--------0.01%0.80%0.77%0.22%0.04%4.79%7.90%0.90%7.34%5.86%6.85%-1.81%3.81%

2 analysts predict YMAB's average Quarter EBITDA for Jun 21 to be $-3.28M, with a high of $-3.28M and a low of $-3.28M. This is -109.69% lower than Y-mAbs Therapeutics's previous annual EBITDA (Mar 21) of $33.88M.

Y-mAbs Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111354224222111122222
Net Income--------$-2.28M$-7.75M$-6.30M$-5.10M$-401.00K$-29.04M$-42.32M$-28.44M$-38.03M$-28.86M$-22.94M$33.41M$-19.93M
Avg Forecast$-5.72M$-6.62M$-6.68M$-5.74M$-4.83M$-7.04M$-5.55M$-37.31M$-8.75M$-8.38M$-10.80M$-33.92M$-31.89M$-31.26M$-29.30M$-30.84M$-30.48M$-25.71M$-29.20M$58.56M$-20.59M
High Forecast$-5.05M$-5.84M$-5.90M$-2.87M$-2.01M$-6.22M$-4.90M$-29.85M$-7.37M$-7.40M$-9.53M$-27.14M$-25.51M$-31.26M$-29.30M$-24.67M$-30.48M$-25.71M$-29.20M$70.27M$-20.59M
Low Forecast$-6.52M$-7.55M$-7.62M$-8.03M$-10.05M$-8.04M$-6.33M$-44.77M$-9.21M$-9.56M$-12.32M$-40.70M$-38.26M$-31.26M$-29.30M$-37.00M$-30.48M$-25.71M$-29.20M$46.85M$-20.59M
Surprise %--------0.26%0.92%0.58%0.15%0.01%0.93%1.44%0.92%1.25%1.12%0.79%0.57%0.97%

Y-mAbs Therapeutics's average Quarter net income forecast for Jun 21 is $-29.20M, with a range of $-29.20M to $-29.20M. YMAB's average Quarter net income forecast represents a -187.40% decrease compared to the company's last Quarter net income of $33.41M (Mar 21).

Y-mAbs Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111354224222111122222
SG&A--------$11.13M$10.20M$11.27M$12.25M$10.79M$13.63M$23.08M$13.44M$15.14M$13.99M$13.47M$11.97M$14.63M
Avg Forecast$35.30M$32.11M$32.51M$30.70M$33.22M$28.79M$28.47M$17.86M$25.91M$25.94M$25.15M$19.27M$13.08M$14.83M$13.86M$13.45M$13.30M$13.42M$9.04M$20.98M$14.31M
High Forecast$39.13M$35.59M$36.03M$34.07M$34.87M$29.17M$31.56M$21.44M$27.40M$25.94M$27.87M$21.36M$15.70M$14.83M$13.86M$13.45M$13.30M$13.42M$9.04M$25.17M$14.31M
Low Forecast$32.12M$29.21M$29.57M$27.32M$31.06M$28.41M$25.90M$14.29M$24.24M$25.94M$22.88M$17.53M$10.47M$14.83M$13.86M$13.45M$13.30M$13.42M$9.04M$16.78M$14.31M
Surprise %--------0.43%0.39%0.45%0.64%0.82%0.92%1.67%1.00%1.14%1.04%1.49%0.57%1.02%

Y-mAbs Therapeutics's average Quarter SG&A projection for Mar 24 is $17.86M, based on 2 Wall Street analysts, with a range of $14.29M to $21.44M. The forecast indicates a 60.42% rise compared to YMAB last annual SG&A of $11.13M (Dec 23).

Y-mAbs Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111354224222111122222
EPS--------$-0.00$-0.00$-0.14$-0.12$-0.01$-0.66$-0.97$-0.65$-0.87$-0.66$-0.53$0.80$-0.48
Avg Forecast$-0.13$-0.15$-0.15$-0.13$-0.11$-0.16$-0.12$-0.14$-0.20$-0.19$-0.24$-0.32$-0.46$-0.71$-0.67$-0.72$-0.69$-0.58$-0.66$0.39$-0.47
High Forecast$-0.11$-0.13$-0.13$-0.06$-0.05$-0.14$-0.11$-0.12$-0.17$-0.17$-0.21$-0.28$-0.40$-0.71$-0.67$-0.72$-0.69$-0.58$-0.66$0.39$-0.47
Low Forecast$-0.15$-0.17$-0.17$-0.18$-0.23$-0.18$-0.14$-0.16$-0.21$-0.21$-0.28$-0.36$-0.52$-0.71$-0.67$-0.72$-0.69$-0.58$-0.66$0.39$-0.47
Surprise %--------0.00%0.00%0.58%0.38%0.02%0.93%1.46%0.91%1.26%1.13%0.80%2.07%1.02%

According to 2 Wall Street analysts, Y-mAbs Therapeutics's projected average Quarter EPS for Jun 21 is $-0.66, with a low estimate of $-0.66 and a high estimate of $-0.66. This represents a -182.92% decrease compared to YMAB previous annual EPS of $0.80 (Mar 21).

Y-mAbs Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BLUEbluebird bio$0.30$14.134610.00%Hold
BCELAtreca$0.09$4.004344.44%Buy
PASGPassage Bio$0.54$6.001011.11%Buy
ZNTLZentalis Pharmaceuticals$3.18$21.86587.42%Buy
BDTXBlack Diamond Therapeutics$2.43$14.75507.00%Buy
STROSutro Biopharma$2.53$11.14340.32%Buy
CCCCC4 Therapeutics$4.01$13.50236.66%Buy
LRMRLarimar Therapeutics$6.13$20.33231.65%Buy
ARQTArcutis Biotherapeutics$10.24$31.00202.73%Buy
DAWNDay One Biopharmaceuticals$13.34$38.80190.85%Buy
ERASErasca$2.60$6.50150.00%Buy
SNDXSyndax Pharmaceuticals$15.60$34.30119.87%Buy
YMABY-mAbs Therapeutics$10.10$20.0098.02%Buy
KRONKronos Bio$0.87$1.6387.36%Buy
MRUSMerus$44.36$76.6772.84%Buy
MRSNMersana Therapeutics$1.98$3.0051.52%Buy
EWTXEdgewise Therapeutics$31.98$45.0040.71%Buy
PCVXVaxcyte$88.39$124.0040.29%Buy
MIRMMirum Pharmaceuticals$43.48$57.2531.67%Buy
TVTXTravere Therapeutics$18.26$21.7519.11%Buy
RVMDRevolution Medicines, Inc. Warrant$56.78$60.636.78%Buy
VECTVectivBio$16.87$18.006.70%Buy

YMAB Forecast FAQ


Is Y-mAbs Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Y-mAbs Therapeutics (YMAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of YMAB's total ratings.

What is YMAB's price target?

Y-mAbs Therapeutics (YMAB) average price target is $20 with a range of $13 to $24, implying a 98.02% from its last price of $10.1. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Y-mAbs Therapeutics stock go up soon?

According to Wall Street analysts' prediction for YMAB stock, the company can go up by 98.02% (from the last price of $10.1 to the average price target of $20), up by 137.62% based on the highest stock price target, and up by 28.71% based on the lowest stock price target.

Can Y-mAbs Therapeutics stock reach $20?

YMAB's highest twelve months analyst stock price target of $24 supports the claim that Y-mAbs Therapeutics can reach $20 in the near future.

What is Y-mAbs Therapeutics's current price target trend?

1 Wall Street analyst forecast a $24 price target for Y-mAbs Therapeutics (YMAB) this month, up 137.62% from its last price of $10.1. Compared to the last 3 and 12 months, the average price target increased by 137.62% and increased by 130.20%, respectively.

What are Y-mAbs Therapeutics's analysts' financial forecasts?

Y-mAbs Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $95.36M (high $99.5M, low $91.23M), average EBITDA is $-70.74M (high $-61.431M, low $-80.056M), average net income is $-54.725M (high $-42.971M, low $-69.191M), average SG&A $108.34M (high $117.04M, low $99.67M), and average EPS is $-0.526 (high $-0.414, low $-0.702). YMAB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $105.6M (high $117.09M, low $95.57M), average EBITDA is $-48.632M (high $-44.015M, low $-53.923M), average net income is $-24.756M (high $-19.655M, low $-29.734M), average SG&A $130.62M (high $144.83M, low $118.22M), and average EPS is $-0.555 (high $-0.44, low $-0.666).

Did the YMAB's actual financial results beat the analysts' financial forecasts?

Based on Y-mAbs Therapeutics's last annual report (Dec 2023), the company's revenue was $84.82M, beating the average analysts forecast of $77.83M by 8.98%. Apple's EBITDA was $-25.672M, missing the average prediction of $-62.352M by -58.83%. The company's net income was $-21.427M, missing the average estimation of $-61.845M by -65.35%. Apple's SG&A was $44.86M, missing the average forecast of $96.27M by -53.41%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.945 by -99.95%. In terms of the last quarterly report (Dec 2023), Y-mAbs Therapeutics's revenue was $23.36M, beating the average analysts' forecast of $20.95M by 11.53%. The company's EBITDA was $-74K, missing the average prediction of $-9.648M by -99.23%. Y-mAbs Therapeutics's net income was $-2.281M, missing the average estimation of $-8.747M by -73.92%. The company's SG&A was $11.14M, missing the average forecast of $25.91M by -57.03%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.196 by -99.95%